Virtual Grand Rounds in Radiation Oncology

The Virtual Grand Rounds in Radiation Oncology are organized by Professor Matthias Guckenberger, University Hospital Zurich, to foster exchange and learning from international leaders in the field of Radiation Oncology and Oncology in general.
Internationally renowned speakers will present their latest and practicechanging research findings and will be available for discussion and answering questions. The virtual format of 30 minutes every first Wednesday of a month will allow integration into everyone’s busy agenda, helping you to stay at the forefront of current knowledge.
We are looking forward to meeting you at our Virtual Grand Round events. Join us to learn more and participate in the discussions.

Upcoming Events

Virtual Grand Rounds in Radiation Oncology

Online via Zoom, Further information below
5 – 5:30 p.m.

Credits

1 SSRO per event

08 Jan 2025

Upcoming Speakers

8. Januar: Dr. Alberto Bossi

presents: Radiotherapy of the primary in metastatic prostate cancer patients: New insights from the PEACE-1 study

Dr. Alberto Bossi is a radiation oncologist specializing in the treatment of urological cancers, particularly prostate cancer. He has been the Head of the Urology and Prostate Brachytherapy Unit at the Gustave Roussy Institute in Villejuif, and currently he works at the AMETHYST Radiotherapy Center in Paris, France.
Dr. Bossi began his medical career in Italy, and completed a clinical fellowship in Radiation Oncology at the Academic Medical Centre in Amsterdam.
He has held positions at institutions in Como and Milan before being appointed Associate Clinical Head at the Department of Radiation Oncology, University Hospital of Leuven, Belgium, where he worked until 2006 before leaving for France.
He served as the Coordinator of the Genito-Urinary Working Group for the European Organisation for Research and Treatment of Cancer (EORTC) and as director of the ESTRO-EAU-ESMO multidisciplinary course on prostate cancer.
He has authored over 300 research papers with more than 8,000 citations, and he is a reviewer for numerous leading journals in Oncology.

Previous Speakers

4. Dezember 2024: Prof. Karin Haustermans

presented: Revving Up Gastric Cancer Care: Insights from the TOPGEAR Trial

Karin Haustermans graduated in 1987 as Doctor in Medicine, Surgery and Obstetrics (MD) at the Catholic University of Leuven (KU Leuven, Belgium). In 1993, she completed her training and qualification in Radiation Oncology. After a research fellowship at the Laboratory of Experimental Radiotherapy (KU Leuven), she obtained her PhD in Medical Sciences for which she received in 1996 the ESTRO-VARIAN Clinical Research Award. Thereafter she spent four years as a staff member at the Netherlands Cancer Institute in Amsterdam.
Currently, Karin Haustermans is Medical Director of Protontherapy PARTICLE and member of the Comprehensive Cancer Center Board of the Leuven Cancer Institute at the University Hospital Leuven (Belgium). She is full Professor at the KU Leuven. She is specialized in GI and GU oncology. She is a member of several (inter)national scientific organizations. From 2006 to 2009 she held the Chair of the EORTC Radiation Oncology Group and from 2009 until 2015 she was Chair of the Quality Assurance Committee of EORTC. She is also involved in the Belgian Cancer Registry as a member of the board and chair of the Coordination Council.
In 2010 she was awarded the ESTRO Breur medal in recognition of her major contribution to European Radiotherapy. From 2011 onwards she was appointed as a member of the Belgian Royal Academy of Medicine, in 2015 she became a fellow of the European Academy of Cancer Sciences and in 2024 member of the Deutsche Akademie der Naturforscher Leopoldina. Since 2016 she is clinical editor of Radiotherapy & Oncology.

6. November 2024: Prof. Nicholas van As

Presented: Definitive SBRT for prostate cancer as new standard of care: results of PACE A & B trials.

Professor Nicholas van As was appointed Medical Director of The Royal Marsden NHS Foundation Trust in January 2016. He has been a Consultant Clinical Oncologist in the Urology Unit at The Royal Marsden since 2008 and is the hospital’s Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. Nicholas is also a Professor of The Institute of Cancer Research.

Professor van As was previously Chair of the UK SBRT Consortium and was previously the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy and risk prediction in early prostate cancer, and he has published numerous papers on these subjects and delivered presentations at international meetings. He is the Chief Investigator for the PACE trial – an international, randomised controlled trial comparing SBRT to image-guided radiotherapy (IGRT) and surgery for treating prostate cancer. conferences. He is active in many educational activities, both at national and international level.Dr. Ricardi is member of numerous national and international scientific societies.
Dr. Ricardi is member of the Steering Committee of ILROG (International Lymphoma Radiation Oncology Group). Dr. Ricardi is former ESTRO (European SocieTy for Radiotherapy and Oncology) President, serving as ESTRO President April 2018-April 2020.

18. September 2024: Prof. Umberto Ricardi

Dr. Ricardi is currently Full Professor and Chairman of Radiation Oncology at University of Turin, Italy. Dr. Ricardi is currently Dean of School of Medicine at University of Turin. He is also serving as Chair of the Department of Oncology at Health and Science Academic Hospital in Turin. Dr. Ricardi’s main areas of clinical and scientific interest include lymphoma, lung cancer, CNS tumors. He is also an expert in the development of cutting edge technologies in Radiation Oncology. Dr. Ricardi has authored more than 400 full research papers, and participated as invited speaker in a number of national and international
conferences. He is active in many educational activities, both at national and international level.Dr. Ricardi is member of numerous national and international scientific societies.
Dr. Ricardi is member of the Steering Committee of ILROG (International Lymphoma Radiation Oncology Group). Dr. Ricardi is former ESTRO (European SocieTy for Radiotherapy and Oncology) President, serving as ESTRO President April 2018-April 2020.

16. July 2024: Prof. Chris Parker

presented: ADT added to postoperative radiotherapy for prostate cancer: results of RADICALS-HD trial
Prof. Chris Parker qualified in medicine from Oxford University in 1989. After general medical training, and stints in Rwanda and New Zealand, he trained in oncology at the Royal Marsden Hospital. Following a clinical research fellowship at Princess Margaret Hospital in Toronto, since 2001 Chris Parker has been a consultant clinical oncologist, specialising in prostate cancer, at the Royal Marsden. Alongside his clinical practice, he has led clinical trials testing the use of active surveillance for localised disease, post-operative radiotherapy for locally advanced disease and radium-223 for bone metastases. He is a former Chair of the National Cancer Research Institute Prostate Cancer Clinical Studies Group. He has published over 300 articles on prostate cancer.

3. July 2024: Prof. Matthias Guckenberger and Prof. Panagiotis Balermpas

presented: Radiation-Oncology changing clinical trials from ASCO Annual Meeting 2024: Critical appraisal from Radiation Oncologists for Radiation Oncologists

Matthias Guckenberger, MD, is Chairman of the Department for Radiation Oncology, University Hospital Zurich (USZ), and Professor at the University of Zurich (UZH). Integration of advanced imaging and radiotherapy into multimodality treatment of lung cancer has been a major research focus, especially stereotactic body radiotherapy (SBRT) for early stage NSCLC and oligo-metastatic disease. Safety and efficacy was evaluated in prospective clinical trials, in large multi-institutional and national patterns of care analyses. Mathematical and imaging-based modeling of tumor and normal tissue response to radiotherapy has been another focus. Overall, his research has been published in >300 peer-reviewed articles.

Prof. Balermpas was born in Athens and studied medicine in the Goethe-University, Frankfurt am Main. He completed his doctoral thesis in the department of Oncology and his residency in the Department of Radiation Oncology of the Frankfurt University Hospital. He completed his habilitation and received the venia legendi for radiation oncology in 2016 and worked further as senior consultant and faculty member there until 2018. In 2018 he moved to Switzerland and to Zurich University Hospital to work as senior consultant for Radiation Oncology. He still works there as chief of service and is in lead of the study office and the radiation oncology satellite of the university hospital at Zurich-Airport. Prof. Balermpas is vice-chair of the SAKK-head and neck group and member of the EORTC, ESTRO, DEGRO and Swiss head and neck society. His main focus is head and neck and skin cancer. He has authored several publications and conducted and participated in guidelines, preclinical studies and clinical trials.

5. June 2024: Prof. Vincent Gregoire

presented: "Immunotherapy and radiochemotherapy for head & neck squamous cell carcinoma: learnings from KEYNOTE 412"

Prof. Vincent GREGOIRE, MD, PhD, is the Head of the Radiation Oncology Dept. at Léon Bérard Cancer Center, Lyon, France. He specializes in head and neck radiation oncology and has coordinated major research on tumor microenvironment and HPV-related radiosensitivity. Prof. GREGOIRE has authored or co-authored more than 330 peer-reviewed publications, supervised 15 PhD theses, and delivered nearly 1000 abstract presentations, lectures or teaching seminars globally. He has served as President of ESTRO and chaired the ICRU Report Committee. His honors include fellowships from the British and Irish Colleges of Radiology and multiple awards from ESTRO.

3. April 2024: Dr. David Palma

presented: Pulmonary SBRT in patients with interstitial lung disease: results of the ASPIRE-ILD trial
as well as "The Top 10 Provocative Facts About Oligometastases That Every Oncologist Should Know" on the 1st of November 2023

Dr. David Palma, MD, PhD is a Professor and Radiation Oncologist at Western University in London, Canada. He holds an MD from the University of Western Ontario, a Master’s Degree in Epidemiology from the Harvard School of Public Health, and a PhD from the VU University in Amsterdam. He has led several international randomized trials in radiation oncology, and he is the chair of the Canadian Pulmonary Radiotherapy Investigators (CAPRI) group. He is the author of the bestselling book Taking Charge of Cancer: What You Need to Know to Get the Best Treatment.

6. March 2024: Dr. Erin Gillespie

presented: Radiation for high-risk asymptomatic bone metastases – state of the evidence and considerations for implementation

Dr. Erin Gillespie is an Associate Professor in Radiation Oncology at University of Washington who specializes in breast cancer and metastatic disease. She recently completed an MPH at Harvard’s TH Chan School of Public Health and is a member of the Hutchinson Institute for Cancer Outcomes Research (HICOR). She is a clinical trialist and implementation scientist focusing on both the development of and ensuring equitable access to evidence-based treatments for patients with cancer. She is the Principal Investigator of a recently approved phase 3 clinical trial through NRG and leads active funding from National Cancer Institute (NCI), Agency for Healthcare Research and Quality (AHRQ), and Radiologic Society of North America (RSNA).

7. February 2024: Dr. Jillian Tsai

presented: Standard-of-care systemic therapy with or without SBRT in patients with oligoprogressive breast cancer or non-small-cell lung cancer

Dr. Jillian Tsai is a Staff Radiation Oncologist at Princess Margaret Cancer Centre and Associate Professor in the Department of Radiation Oncology at the University of Toronto. She leads the Allan and Ruth Kerbel Palliative Radiation and Oligometastases Program (PROP) and is a member of the Head and Neck Site Group. She is also the Medical Director of Princess Margaret Cancer Registry. Prior to joining Princess Margaret Cancer Centre in September 2022, she practiced radiation oncology at Memorial Sloan Kettering Cancer Center in New York City from 2014 to 2022. Dr. Tsai completed residency training at MD Anderson Cancer Center after receiving her MD degree from Vanderbilt University. She also holds a PhD degree in Cancer Epidemiology from Stanford University.

Dr. Tsai is a recipient of Eleanor Montague Distinguished Resident Award in Radiation Oncology by American Association for Women Radiologists, as well as Steven A. Leibel Memorial Award by American Society for Radiation Oncology. She also served as a track chair for American Society of Radiation Oncology’s Annual Meeting Education Committee and the Deputy Editor-in-Chief for Advances in Radiation Oncology.

10. January 2024: Prof. Carolyn Taylor

presented: Effect of regional lymph node radiotherapy. An EBCTCG meta-analysis of 14,324 women in 16 trials

Carolyn Taylor is a consultant clinical oncologist and professor of oncology. She studied medicine at Oxford University. Her clinical training was in general medicine and then clinical oncology. She gained Fellowship of the Royal College of Radiologists in 2004.

Since then she has worked as a clinical research fellow at the Clinical Trial Service Unit, doing research alongside clinical work. She completed her DPhil on the risk of heart disease after breast cancer radiotherapy in 2008.
She now provides clinical leadership in large international collaborations including oncologists, epidemiologists, statisticians and cancer registry staff.
She works in the Early Breast Cancer Trialists’ Collaborative Group on trials of surgery and radiotherapy.
She is Principal Investigator on a Cancer Research UK research program on the benefits and risks of cancer treatments. This programme combines information from high quality datasets to produce estimates of benefits and risks for use by oncologists in the clinic today.

6. December 2023: Andreas Rimner, MD

presented: Can radiotherapy for lung cancer be guided by circulating tumor DNA today?

Andreas Rimner, MD, is the Director of Thoracic Radiation Oncology Research and Associate Attending at Memorial Sloan Kettering Cancer Center specialized in treating thoracic malignancies, including non-small cell lung cancer (NSCLC) and small cell lung cancer, malignant pleural mesothelioma (MPM), thymic tumors and metastatic disease. He is the Past Thoracic Track Chair of the Annual Meeting of ASTRO, ABR board member for Thoracic Cancers and Sarcomas, Vice President of ITMIG, Board Member of IMIG and Member of the IASLC Staging and Prognostic Factors Committee. He is the Principal Investigator of 8 ongoing prospective clinical trials. He is a Member of the Lung Core Committee of NRG Oncology and the national Principal Investigator of a phase III NRG Oncology trial (NRG LU-006) on the role of hemithoracic pleural IMPRINT in patients with resectable malignant pleural mesothelioma.

6. September 2023: Prof. Nicholas van As

presented: SBRT versus Surgery for prostate cancer: results of the PACE-A Trial

Professor Nicholas van As was appointed Medical Director of The Royal Marsden NHS Foundation Trust in January 2016. He has been a Consultant Clinical Oncologist in the Urology Unit at The Royal Marsden since 2008 and is the hospital’s Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. Nicholas is also a Professor of The Institute of Cancer Research and a trustee for The Royal Marsden Cancer Charity.

Professor van As was previously Chair of the UK SBRT Consortium and was previously the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI, and he has published numerous papers on these subjects and delivered presentations at international meetings. He is the Chief Investigator for the PACE trial – an international, randomised controlled trial comparing SBRT to image-guided radiotherapy (IGRT) and surgery for treating prostate cancer.

Organization

Matthias Guckenberger, Prof. Dr. med.

Klinikdirektor, Klinik für Radio-Onkologie

Mail matthias.guckenberger@usz.ch

Spezialgebiete: Therapie des Lungen Karzinom, Therapie des Prostata Karzinom, Therapie von Oligometastasen

Comprehensive Cancer Center

Klinik für Radio-Onkologie

Häufig gesucht

Virtual Grand Rounds in Radiation Oncology

Upcoming Events